Abacavir/lamivudine

Abacavir/lamivudine
Combination of
Abacavir	Nucleotide analogue reverse transcriptase inhibitor
Lamivudine	Nucleotide analogue reverse transcriptase inhibitor
Clinical data
Trade names	Kivexa, Epzicom, others
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a696011
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	J05AR02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Identifiers
CAS Number	136470-78-5 136470-78-5 ; 134678-17-4 ;
PubChem CID	5273759;
UNII	WR2TIP26VS; 2T8Q726O95 ;
KEGG	D08775;
NIAID ChemDB	225604;
CompTox Dashboard (EPA)	DTXSID90234433 ;
	(what is this?) (verify)

Abacavir/lamivudine, sold under the brand name Kivexa among others, is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It contains abacavir and lamivudine. It is generally recommended for use with other antiretrovirals. It is commonly used as part of the preferred treatment in children. It is taken by mouth as a tablet.

Common side effects include trouble sleeping, headache, depression, feeling tired, nausea, rash, and fever. Serious side effects may include high blood lactate levels, allergic reactions, and enlargement of the liver. It is not recommended in people with a specific gene known as HLA-B*5701. Safety in pregnancy has not been well studied but it appears to be okay. Lamivudine and abacavir are both nucleoside reverse transcriptase inhibitors (NRTI).

Abacavir/lamivudine was approved for medical use in the United States in 2004. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.